delafloxacin

a fluoroquinolone anti-infective agent

Also Known As:

1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 3-quinolinecarboxylic acid, 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-; ABT 492; ABT-492; ABT492; Baxdela; RX-3341

Networked: 94 relevant articles (15 outcomes, 23 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        Fluoroquinolones: 5348
        delafloxacin: 94

Experts

1.	Quintas, Megan: 9 articles (08/2020 - 01/2017)
2.	Cammarata, Sue: 8 articles (08/2020 - 01/2015)
3.	Lawrence, Laura: 8 articles (08/2020 - 01/2015)
4.	Bassetti, Matteo: 7 articles (01/2022 - 03/2015)
5.	Cammarata, Sue K: 6 articles (01/2018 - 03/2016)
6.	Paulson, Susan K: 5 articles (01/2018 - 01/2017)
7.	Righi, Elda: 5 articles (01/2018 - 03/2015)
8.	Duffy, Erin: 3 articles (01/2021 - 01/2016)
9.	McCurdy, Sandra: 3 articles (01/2021 - 01/2020)
10.	Flamm, Robert K: 3 articles (12/2020 - 10/2003)

Related Diseases

1.	Infections 08/01/2020 - "The aim of this study was to evaluate all the literature on delafloxacin in databases and make comparisons of its efficacy with antimicrobial drugs routinely used to treat skin infections. " 10/05/2021 - "Comparative efficacy of delafloxacin for complicated and acute bacterial skin and skin structure infections: results from a network meta-analysis." 01/01/2021 - "This study illustrates the potential utility of delafloxacin in treatment of infections due to some NTM." 01/01/2019 - "Efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials." 11/01/2016 - "This study aimed to define the pharmacodynamic profile of delafloxacin against CAP pathogens using a neutropenic murine lung infection model. "
2.	Bacterial Pneumonia 06/01/2022 - "A profile of delafloxacin in the treatment of adults with community-acquired bacterial pneumonia." 01/01/2022 - "The present narrative review summarizes the available data on the use of delafloxacin for the treatment of community-acquired bacterial pneumonia (CABP). " 01/01/2022 - "Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia." 10/01/2020 - "The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model." 12/08/2021 - "Delafloxacin has been approved to treat acute bacterial skin and skin-structure infections, as well as community-acquired bacterial pneumonia. "
3.	Chronic Obstructive Pulmonary Disease (COPD) 06/01/2022 - "Delafloxacin is an effective and generally well-tolerated treatment that increases the number of available treatments for CAP and, although further research is required, may be a useful option for patients with CAP and comorbid asthma or COPD. " 06/01/2022 - "Delafloxacin expands the range of treatments for CAP, and is potentially useful for patients with comorbid asthma or COPD." 10/01/2020 - "In the scenario analysis that was restricted to COPD/asthma patients, adding delafloxacin to the formulary was estimated to result in a total budget impact of $5,042. " 10/01/2020 - "Scenario analyses were conducted to evaluate the potential budget impact among COPD/asthma patients based on the findings from the phase III trial of delafloxacin for CABP, which indicated that patients with COPD or asthma may experience improved effectiveness with delafloxacin compared to moxifloxacin. " 06/01/2022 - "Delafloxacin may be more effective than moxifloxacin in patients with a history of asthma or chronic obstructive pulmonary disease (COPD), although further research is needed. "
4.	Asthma (Bronchial Asthma) 06/01/2022 - "Delafloxacin is an effective and generally well-tolerated treatment that increases the number of available treatments for CAP and, although further research is required, may be a useful option for patients with CAP and comorbid asthma or COPD. " 06/01/2022 - "Delafloxacin expands the range of treatments for CAP, and is potentially useful for patients with comorbid asthma or COPD." 10/01/2020 - "In the scenario analysis that was restricted to COPD/asthma patients, adding delafloxacin to the formulary was estimated to result in a total budget impact of $5,042. " 10/01/2020 - "Scenario analyses were conducted to evaluate the potential budget impact among COPD/asthma patients based on the findings from the phase III trial of delafloxacin for CABP, which indicated that patients with COPD or asthma may experience improved effectiveness with delafloxacin compared to moxifloxacin. " 06/01/2022 - "Delafloxacin may be more effective than moxifloxacin in patients with a history of asthma or chronic obstructive pulmonary disease (COPD), although further research is needed. "
5.	Anthrax 01/01/2023 - "To evaluate the in vitro activity and in vivo efficacy of delafloxacin against Bacillus anthracis, the causative agent of anthrax. " 01/01/2023 - "Given the high bar set by the 100 × LD50 challenge dose in this study, the results from delafloxacin treatment are promising for the treatment of inhaled anthrax."

Related Drugs and Biologics

1.	Moxifloxacin (Avelox)
2.	Fluoroquinolones
3.	Quinolones
4.	Vancomycin
5.	Anti-Bacterial Agents (Antibiotics)
6.	Ceftaroline
7.	ceftobiprole
8.	Ciprofloxacin (Cipro)
9.	tedizolid
10.	dalbavancin

Related Therapies and Procedures

1.	Oral Administration
2.	Therapeutics
3.	Renal Dialysis (Hemodialysis)
4.	Intravenous Administration
5.	Punctures